This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasugai, Y. Articles by Seto, M. Search for Related Content PubMed PubMed Citation Articles by Kasugai, Y. Articles by Seto, M.

Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma

Authors' Affiliations: ¹ Division of Molecular Medicine, Aichi Cancer Center Research Institute, Departments of ² Hematology and Cell Therapy and ³ Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan

Requests for reprints: Masao Seto, Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1 Kanoko-den, Chikusa-ku, 464-8681 Nagoya, Japan. Phone: 81-52-762-6111, ext. 7080/7082; Fax: 81-52-764-2982; E-mail: mseto{at}aichi-cc.jp.

Purpose: Increases in gene dosage through DNA amplification represents a common feature of many tumors and can result in the up-regulation of tumor-promoting genes. Our recent genome-wide, array-based comparative genomic hybridization analysis of 66 cases of diffuse large B-cell lymphoma found that genomic gain of 6p21 was observed in as many as 17 cases, including 14 cases with low-level copy number gain and three cases with high-level copy number gains (amplifications).

Experimental Design and Results: To identify the target gene(s) for 6p21 amplification, we constructed a detailed amplicon map at the region of genomic amplification with the aid of high-resolution contig array-based comparative genomic hybridization glass slides, consisting of contiguously ordered bacterial artificial chromosome/P1-derived artificial chromosome clones covering 3 Mb throughout the 6p21 amplification region. Alignment of the amplifications identified a minimally overlapping 800 kb segment containing 15 genes. Quantitative expression analysis of the genes from both patient samples and the SUDHL9 cell line revealed that CCND3 and BYSL (1.9 kb telomeric to the CCND3 gene locus) are the targets of 6p21 genomic gain/amplification.

Conclusions: Although it is known that t(6;14)(p21;q32) induces aberrant overexpression of CCND3 in B-cell malignancies, we were able to show that CCND3, which encodes the cyclin D family member protein that controls the G₁-S phase of cell cycle regulation, can also be a target of genomic gain/amplification. Overexpression of CCND3 through genomic amplification is likely to lead to aberrant cell cycle control, although the precise biological role of BYSL with respect to tumorigenesis remains to be determined.

This article has been cited by other articles:

				X.-Y. Lu, Y. Lu, Y.-J. Zhao, K. Jaeweon, J. Kang, L. Xiao-Nan, G. Ge, R. Meyer, L. Perlaky, J. Hicks, et al. Cell Cycle Regulator Gene CDC5L, a Potential Target for 6p12-p21 Amplicon in Osteosarcoma Mol. Cancer Res., June 1, 2008; 6(6): 937 - 946. [Abstract] [Full Text] [PDF]